Related coverage linked through entity extraction aliases.
Jul 24, 2026
A stem cell therapy for geographic atrophy improved vision in a phase Ib trial, and the first gene therapy for optic neuropathies was administered. Next-generation anti-VEGF agents are also extending treatment intervals in retinal vascular disease.
May 24, 2026
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, adding advanced retinal organoid and 2D RPE models to its iPSC portfolio. The deal follows Axol's acquisition of Phenocell and a $2.8 million financing led by BroadOak Capital Partners. Financial terms were not disclosed.
Jul 31, 2026
Life Biosciences has treated the first patient with ER-100, a cell-rejuvenating gene therapy for glaucoma. The FDA-approved Phase 1 trial will assess safety in up to 18 patients.
Apr 14, 2026
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
Mar 11, 2026
Researchers at Duke University discovered that specialized immune cells called resident macrophages maintain the eye's drainage system and regulate pressure, potentially providing a new therapeutic target for glaucoma treatment beyond current symptom management approaches.
Feb 26, 2026
The FDA cleared NexEos Bio's IND application to proceed with a Phase II/III trial of NTX-1024 ophthalmic solution for vernal keratoconjunctivitis, following positive results from a 15-patient study in Mexico.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
